Supernus Pauses New Patient Starts for Parkinson's Pump Onapgo Amid High Demand
Supernus Pharmaceuticals has announced a temporary halt on new patient starts for its recently launched Parkinson's disease infusion pump, Onapgo, due to unexpectedly high demand and supply constraints. The company is prioritizing care for existing patients while working to build adequate inventory.
Onapgo Launch and Demand
Onapgo, a wearable pump that delivers subcutaneous infusions of apomorphine to treat motor fluctuations in adults with advanced Parkinson's disease, received FDA approval in February 2025 after multiple attempts. Launched in April, the product has seen strong uptake, with over 1,300 enrollment forms received from more than 450 prescribers by September 30.
The device is designed to give patients more control over their daily "off" time, periods when medication wears off and Parkinson's symptoms worsen. This unique approach has contributed to its rapid adoption, leading to supply challenges for Supernus.
Financial Impact and Company Outlook
Despite the pause on new patient starts, Onapgo has shown promising financial results. In its first full quarter on the market, the product generated sales of $6.8 million, contributing to Supernus' overall revenue growth.
Supernus reported third-quarter revenues of $192.1 million, a 9% increase compared to the same period in 2024. In light of these results, the company has revised its 2025 revenue forecast upward to between $685 million and $705 million, from the previous range of $670 million to $700 million.
Looking Ahead
Supernus is actively working to address the supply imbalance and plans to resume full prescribing of Onapgo "as soon as possible." The company's CEO, Jack Khattar, described the launch as an "encouraging start" despite the current challenges.
As Supernus navigates this period of high demand, the pharmaceutical industry will be watching closely to see how quickly the company can scale up production and resume new patient starts for this innovative Parkinson's treatment.
References
- Supernus pauses new patient starts for Parkinson's pump Onapgo, citing high demand
Some eight months into the launch of Onapgo, the Parkinson’s disease infusion pump Supernus Pharmaceuticals spent years fighting to get across the FDA finish line, the drugmaker is discovering that patients’ appetite for the wearable is more than it can currently handle.
Explore Further
What were the clinical trial results that supported the FDA approval of Onapgo in February 2025?
Who are the main competitors offering similar wearable infusion pumps for Parkinson's disease and how does Onapgo compare?
What is the estimated market size for subcutaneous infusion therapies targeting advanced Parkinson's disease?
What steps is Supernus taking to resolve the supply chain constraints affecting Onapgo distribution?
How does Supernus plan to scale up production to meet the high demand for Onapgo in the near future?